Skip to content

RNTX RNTX Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's accrued expenses and other liabilities?
RNTX (RNTX) reported accrued expenses and other liabilities of $247K in Q1 2026.
How has RNTX's accrued expenses and other liabilities changed year-over-year?
RNTX's accrued expenses and other liabilities increased by 2570.0% year-over-year, from -$10K to $247K.